PMID- 30289034
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1744-8417 (Electronic)
IS  - 1744-6651 (Linking)
VI  - 10
IP  - 6
DP  - 2015 Nov
TI  - Dulaglutide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes.
PG  - 581-590
LID - 10.1586/17446651.2015.1098532 [doi]
AB  - The prevalence of diabetes continues to rise worldwide. Over the past five years, 
      available treatment options have expanded to allow individualized management of 
      patients with diabetes. The glucagon-like peptide-1 (GLP-1) receptor agonists 
      have become an essential tool in the management of type 2 diabetes mellitus 
      (T2DM). This class provides several advantages for glycemic control with minimal 
      risk of hypoglycemia. Based on the most recent guidelines for T2DM, GLP-1 
      receptor agonists can be prescribed as monotherapy or in combination with oral 
      antidiabetic agents or insulin for the management of T2DM. Dulaglutide has become 
      the most recent and available GLP-1 receptor agonist on the market. Dulaglutide 
      is a once-weekly GLP-1 receptor agonist that can be used as monotherapy or as a 
      second-line agent for T2DM. This review article summarizes the efficacy, safety, 
      and clinical attributes of dulaglutide among patients with T2DM.
FAU - Clements, Jennifer
AU  - Clements J
AD  - a Department of Pharmacy Practice , Presbyterian College School of Pharmacy - 
      Pharmacy Practice , Clinton , SC , USA.
FAU - Moore, Katherine
AU  - Moore K
AD  - a Department of Pharmacy Practice , Presbyterian College School of Pharmacy - 
      Pharmacy Practice , Clinton , SC , USA.
FAU - Shealy, Kayce
AU  - Shealy K
AD  - a Department of Pharmacy Practice , Presbyterian College School of Pharmacy - 
      Pharmacy Practice , Clinton , SC , USA.
LA  - eng
PT  - Journal Article
DEP - 20151013
PL  - England
TA  - Expert Rev Endocrinol Metab
JT  - Expert review of endocrinology & metabolism
JID - 101278293
OTO - NOTNLM
OT  - diabetes mellitus
OT  - dulaglutide
OT  - glucagon-like peptide-1 receptor agonist
OT  - hyperglycemia
OT  - incretin mimetic
OT  - type 2 diabetes mellitus
EDAT- 2015/11/01 00:00
MHDA- 2015/11/01 00:01
CRDT- 2018/10/06 06:00
PHST- 2018/10/06 06:00 [entrez]
PHST- 2015/11/01 00:00 [pubmed]
PHST- 2015/11/01 00:01 [medline]
AID - 10.1586/17446651.2015.1098532 [doi]
PST - ppublish
SO  - Expert Rev Endocrinol Metab. 2015 Nov;10(6):581-590. doi: 
      10.1586/17446651.2015.1098532. Epub 2015 Oct 13.